InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (6 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
6
T+90 hit rate
30%
T+90 mean return
-12.2%
Across 10 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Lurker Nancy, Chairman & CEO. Director active across 3 companies, notably EyePoint Pharmaceuticals, Inc.. Cumulatively, 25 disclosures have been logged. Breakdown: 1 buy · 6 sells. Total volume traded: €1.1m. Activity tracked since 14 June 2021. The latest transaction was filed on 21 May 2026 (Retenue fiscale). Regulator: SEC (Form 4). All data is free.
Declarations25 total
6,142 sharesOrdinary SharesSEC:0001520262-26-000089:0
1,475 shares@ US$36.950.0010% mcap100.0% of flowOrdinary SharesSEC:0001520262-26-000089:1
4,500 shares@ US$35.96910.0094% mcap50.0% of flowCommon StockSEC:0001450485-26-000007:0
4,500 shares@ US$35.96910.0094% mcap100.0% of flowCommon StockSEC:0001450485-26-000007
9,791 shares0Common StockSEC:0001062993-25-009809:0
2,323 sharesOrdinary SharesSEC:0001127602-25-012018:0
20,000 shares0Common StockSEC:0001562180-25-001134:0
12,726 shares0Common StockSEC:0001062993-25-001754:0
12,667 shares0Common StockSEC:0001562180-25-000228:0
3,173 shares@ US$7.882.6% of flowCommon StockSEC:0001562180-24-006378:0
Ideal exit: 13 May 2025 (T+270)
11,111 shares0Common StockSEC:0001562180-24-005700:0
20,000 shares0Common StockSEC:0001562180-24-001294:0
5,044 shares@ US$24.970213.3% of flowCommon StockSEC:0001562180-24-000636:0
75,133 shares0Common StockSEC:0001562180-24-000402:0
52,208 shares0Common StockSEC:0001562180-24-000133:0
20,000 shares@ US$20.7643.7% of flowCommon StockSEC:0001562180-23-008170:0
17,533 shares0Common StockSEC:0001562180-23-001330:0
12,466 shares0Common StockSEC:0001562180-22-002135:0
13,717 shares0Common StockSEC:0001562180-22-001757:0
17,533 shares0Common StockSEC:0001562180-22-001410:0
17,533 shares0Common StockSEC:0001562180-22-001410
10,000 shares@ US$20.1480.012% mcap50.0% of flowCommon StockSEC:0001562180-21-007116:0
10,000 shares@ US$20.14820.2% of flowCommon StockSEC:0001562180-21-007116
4,500 shares0Common StockSEC:0001562180-21-004275
4,500 shares0Common StockSEC:0001562180-21-004275:0
25 of 25 declarations
About Lurker Nancy
Nancy Lurker serves as President and CEO of EyePoint Pharmaceuticals, Inc. and Collegium Pharmaceutical, Inc. She leads these companies, overseeing their operations and developing strategies for growth. Her experience in the pharmaceutical sector is crucial for innovation and the development of new treatments.
